Pfizer's JAK abrocitinib comes through in teen eczema test

Hoping to carve out a niche in a tough market full of competitors, Pfizer has posted yet more positive data in atopic dermatitis.

This latest phase 3 in a line of studies from the Dupixent-rivaling hopeful was across just under 300 adolescent patients aged 12 to 18 with atopic dermatitis, aka eczema.